News
Author: Berte Poulsson
Download Our Investor Presentation
Download presentation
"*" indicates required fields
Latest news
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director
Oslo, Norway and Boston, USA, 16 December 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...
Read more
Calluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Oslo, Norway and Boston, USA, 31 October 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...
Read more
Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis
Oslo, Norway and Boston, Massachusetts, 26 August 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...
Read more
Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference
Oslo, Norway and Boston, MA, 29 April 2025: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to...
Read more
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications
Oslo, Norway, 23 October 2024: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory...
Read more
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board
Executive appointments will drive growth strategy and progression of clinical pipeline Oslo, Norway and Boston, MA, 9 October 2024: Calluna...
Read more